Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart Disease

Simple item page
dc.contributor.authorBeaton, Andrea
dc.contributor.authorOkello, Emmy
dc.contributor.authorRwebembera, Joselyn
dc.contributor.authorAlepere, Juliet
dc.contributor.authorLwabi, Peter
dc.contributor.authorNakitto, Miriam
dc.contributor.authorNdagire, Emma
dc.contributor.authorOmara, Isaac O.
dc.contributor.authorKarthikeyan, Ganesan
dc.contributor.authorSteer, Andrew C.
dc.date.accessioned2023-04-05T18:18:25Z
dc.date.available2023-04-05T18:18:25Z
dc.date.issued2022
dc.description.abstractRheumatic heart disease affects more than 40.5 million people worldwide and results in 306,000 deaths annually. Echocardiographic screening detects rheumatic heart disease at an early, latent stage. Whether secondary antibiotic prophylaxis is effective in preventing progression of latent rheumatic heart disease is unknown.en_US
dc.identifier.citationBeaton, A., Okello, E., Rwebembera, J., Grobler, A., Engelman, D., Alepere, J., ... & Steer, A. C. (2022). Secondary antibiotic prophylaxis for latent rheumatic heart disease. New England Journal of Medicine, 386(3), 230-240.DOI: 10.1056/NEJMoa2102074en_US
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/8426
dc.language.isoenen_US
dc.publisherNew England Journal of Medicineen_US
dc.subjectLatent Rheumatic Heart Diseaseen_US
dc.subjectAntibiotic Prophylaxisen_US
dc.titleSecondary Antibiotic Prophylaxis for Latent Rheumatic Heart Diseaseen_US
dc.typeArticleen_US
Files
Collections
Medical and Health Sciences